secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2026-05-28T20:15:13+00:00
Accession:  0001503802-26-000027
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm shareholders approve equity plan amendments; board approves milestone-based PSU awards for executives
--------------------------------------------------------------------------------

- Shareholders approved 3M share increase under 2022 Equity Incentive Plan and 1.4M under ESPP at May 21 annual meeting.
- Directors Barry E. Greene and Christy J. Oliger elected as Class I directors for three-year terms.
- Board approved retention program granting PSUs vesting on clinical milestones; CEO Richard Paulson awarded 343,000 PSUs per award.
- Named executives (CMO, CFO, CDO) each received 130,000-150,000 PSUs per award; total 3,838,380 PSUs granted to all eligible employees.
- Board adopted further amendment to increase authorized shares by 950,000, subject to stockholder approval by May 31, 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000150380226000027/0001503802-26-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000150380226000027/kpti-20260521.htm
  HTML page:      https://secwatch.observer/filing/0001503802-26-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer